Raksha Jain
Overview
Explore the profile of Raksha Jain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1690
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Park S, Jain R, Mirfakhraee S
J Cyst Fibros
. 2024 Aug;
24(1):40-46.
PMID: 39214747
Glucagon-like-peptide-1 (GLP-1) agonists are commonly used to improve glycemic control and promote weight loss in individuals with type 2 diabetes mellitus (T2DM) and/or obesity. However, there is a paucity of...
12.
Kazmerski T, Stransky O, Lee M, Prangley K, Jain R, Georgiopoulos A, et al.
BMJ Open Respir Res
. 2024 Aug;
11(1).
PMID: 39209351
Introduction: People with cystic fibrosis (CF) are living longer and healthier lives with a growing number considering and pursuing parenthood. The decision of whether to become a parent is complex...
13.
Taylor-Cousar J, Sole A, Jain R
Curr Opin Pulm Med
. 2024 Aug;
30(6):652-659.
PMID: 39193883
Purpose Of Review: The purpose of this review is to summarize available data on fertility, fertility preservation, pregnancy and parenthood following lung transplantation for people with cystic fibrosis (pwCF). Recent...
14.
Devarajan S, Staggers K, Wu T, Jain R
Ann Am Thorac Soc
. 2024 Aug;
21(12):1778-1781.
PMID: 39141651
No abstract available.
15.
Mayer-Hamblett N, Gifford A, Kloster M, Russell R, Braun A, Gibson R, et al.
Ann Am Thorac Soc
. 2024 Jul;
21(11):1507-1515.
PMID: 39041864
Evaluating approaches to reduce treatment burden is a research priority among people with cystic fibrosis on highly effective modulators, including elexacaftor-tezacaftor-ivacaftor (ETI). We sought to evaluate the impact of discontinuing...
16.
Todd J, Morgan W, Szczesniak R, Ostrenga J, OConnell O, Cromwell E, et al.
Ann Am Thorac Soc
. 2024 Jun;
21(10):1416-1420.
PMID: 38889346
Declines in percent predicted forced expiratory volume in 1 second (ppFEV) are an important marker of clinical progression of cystic fibrosis (CF). We examined ppFEV variability in relation to a...
17.
Holtrop M, Cosmich S, Lee M, Keller A, Jain R
Chest
. 2024 Jun;
166(5):951-962.
PMID: 38871282
Background: Historically, studies show that female patients with cystic fibrosis (CF) have worse pulmonary outcomes than male patients, including decreased life expectancy. It is unknown whether this disparity persists in...
18.
Sun Y, Chatterjee S, Lian X, Traylor Z, Sattiraju S, Xiao Y, et al.
Science
. 2024 Jun;
384(6701):1196-1202.
PMID: 38870301
In vivo genome correction holds promise for generating durable disease cures; yet, effective stem cell editing remains challenging. In this work, we demonstrate that optimized lung-targeting lipid nanoparticles (LNPs) enable...
19.
Abid S, Shaffer L, Bayat A, Lee M, Keller A, Jain R
J Cyst Fibros
. 2024 Apr;
23(5):874-877.
PMID: 38653651
Background: Levels of sulfated Dehydroepiandrosterone (DHEA-S) are unknown in people with Cystic Fibrosis (pwCF). DHEA-S is reported to have an inverse association with inflammation and warrants evaluation in pwCF. Methods:...
20.
Rosenfeld M, Cromwell E, Schechter M, Ren C, Flume P, Szczesniak R, et al.
J Cyst Fibros
. 2024 Mar;
23(3):443-449.
PMID: 38556415
Rationale: The American Thoracic Society recommended switching to race-neutral spirometry reference equations, as race is a social construct and to avoid normalizing disparities in lung function due to structural racism....